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SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PM www.jacctctabstracts2014.comprocedural complication. Multiple logistic regression analysis showed that the pres-
ence of peripheral vascular disease (PVD) (p¼0.024, OR¼1.9), DM (p¼0.002,
OR¼2.2), ACS presentation (p¼0.013, OR¼1.9) and SYNTAX score (p< 0.001,
OR¼1.047) had a signiﬁcant impact on MACE.
Conclusions: RA is a complex but safe procedure typically performed in elderly high-
risk patients with calciﬁed lesions. Higher syntax scores >22 and>32 were associated
with higher rates of death, MI, TVR and ST. PVD, DM, ACS presentation and syntax
score are signiﬁcant predictors for MACE.Table 1. Outcomes by SYNTAX category.
SYNTAX22 SYNTAX>22 p-value SYNTAX32 SYNTAX>32 p-value
Total 334 181 443 72
Cardiac Death 12 (3.6%) 21 (11.6%) 0.001 21 (4.7%) 12 (16.7%) 0.001
Death 33 (9.9%) 37 (20.4%) 0.002 47 (10.6%) 23 (31.9%) <0.001
TVR 22 (6.6%) 17 (9.4%) 0.295 33 (7.4%) 6 (8.3%) 0.81
MI 25 (7.5%) 33 (18.2%) <0.001 41 (9.3%) 17 (23.6%) 0.001
Stent Thrombosis 0 (0%) 6 (3.3%) 0.002 4 (0.9%) 2 (2.8%) 0.199
Stroke 8 (2.5%) 7 (4.2%) 0.284 11 (2.6%) 4 (5.9%) 0.139
MACE 45 (13.5%) 51 (28.2%) <0.001 70 (15.8%) 26 (36.1%) <0.001
Vascular complications 7 (2.1%) 4 (2.2%) 1 10 (2.3%) 1 (1.4%) 1
Procedural
complications
16 (4.8%) 16 (8.8%) 0.085 22 (5.0%) 10 (13.9%) 0.008TCT-131
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Background: Percutaneous removal of atherosclerotic material using atherectomy
devices may offer an alternative approach for improving procedural success. The
TRUTH study (24 patients) evaluated the removal of plaque with the Orbital Athe-
rectomy System (OAS) (Cardiovascular Systems, Inc., St. Paul, MN) by analyzing
changes in plaque volume/composition via an independent virtual histology (VH)-
intravascular ultrasound (IVUS) Core Laboratory at CRF.
Methods: Lesions in the superﬁcial femoral artery, popliteal, and/or tibioperoneal
trunk were treated with the OAS followed by adjunctive balloon angioplasty (BA).
IVUS images were collected during 1) pre-treatment; 2) post-OAS; and 3) post-BA.
Results: The mean age was 70.4 years and 36% of patients had a history of renal
insufﬁciency, diabetes (72%), hyperlipidemia (100%), hypertension (100%), and
smoking (84%). The mean lesion and calcium length assessed via angiography was
65.4+27.8mm and 55.431.6 mm, respectively. The baseline Rutherford Classiﬁcation
(RC) of 3 (96.0%) changed RC of 0 (100% asymptomatic) at 2 week follow-up. No
incidence of recoil, slow ﬂow/no reﬂow, ﬂow-limiting dissections or perforations were
reported. VH-IVUS analysis revealed that the minimum lumen area increased from 4.0
mm2 to 9.1 mm2 post-procedure (< 0.0001) accompanied with decrease of area stenosis
(Table). At the maximum calcium ablation site, the lumen area also increased and cal-
cium reduction was responsible for 86% [35%, 100%] of the lumen increase. The arc of
reverberation increased from 22 to 39 (p¼0.05) and the prevalence of convex shape of
calcium surface decreased indicating device-related modiﬁcation of calcium.Pre Post-OAS Post-BA
p-value
(overall)
p-value (pre vs
post-OAS)
Lesion analysis (n¼24 lesions)
Minimum lumen area, mm2 4.0 [2.2,
4.9]
4.7 [3.2,
5.9]
9.1 [7.8,
10.5]
<0.0001 0.072
Area stenosis, % 77 [61, 81] 64 [58, 77] 43 [27, 56] <0.0001 0.067
Mean vessel area, mm3/mm 31.4 [26.1,
35.2]
31.8 [25.9,
37.8]
34.5 [31.9,
40.3]
<0.0001 0.21
Mean lumen area, mm3/mm 8.5 [5.0,
9.9]
8.9 [8.1,
11.1]
12.9 [11.7,
15.2]
<0.0001 0.037
Mean plaque area, mm3/mm 22.1 [18.5,
28.1]
22.1 [18.1,
26.2]
21.9 [17.9,
25.3]
0.04 0.7
Calciﬁed plaque analysis (28 calciﬁed plaques)
Lumen area, mm2 6.2 [4.7,
8.7]
8.4 [6.4,
10.9]
12.2 [11.2,
14.9]
<0.0001 0.0013
Area stenosis, % 58 [29, 69] 38 [11, 45] 16 [10, 42] <0.0001 <0.0001
Convex shape of surface of
calcium, %
54 39 29 0.011 0.21
Reverberation, % 25 39 36 0.095 0.11
Arc of reverberation,  22 [18, 24] 39 [27, 60] 28 [20, 47] 0.43 0.05
% of Calcium Reduction out of
Lumen Gain
– 86 [35,100] – – –
OAS¼orbital atherectomy system; BA¼balloon angioplasty
B40 JACC Vol 64/11Conclusions: The orbital atherectomy system (OAS) is effective at reducing and
modifying calcium from lesions, resulting in low acute complications and improved
Rutherford Classiﬁcation.
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Background: Directional atherectomy is an endovascular therapy that is effective in
the treatment of diabetic and non-diabetic patients with peripheral artery disease
(PAD). This study was undertaken to assess the all-cause healthcare costs of direc-
tional atherectomy as well as other therapies used in treating diabetic patients with
PAD over 24-months post-treatment.
Methods: PAD patients were selected from a large claims database with 1 CPT code
for a lower extremity PAD procedure between 2005-2011. The date of the ﬁrst CPT
code was the index date. Patients were included with: 12-months of pre-index date
continuous medical and pharmacy eligibility; 1 PAD ICD-9-CM code within
6 months prior to the index date; 1 medical claim for Type 2 Diabetes Mellitus
during baseline; and 18 years of age on index date. Multivariate models to evaluate
risk of hospitalization during follow-up and all-cause health care cost at 24 months
were constructed, controlling for covariates.
Results: 8,121 patients had both diabetes and PAD, with a mean age of
67.6 years and 39% were female. Endovascular treatments received for PAD treat-
ments were: stent (26%), peripheral bypass (23%), PTA+stent (22%), PTA (16%),
PTA+atherectomy (4%), atherectomy (4%), unspeciﬁed (4%), and PTA+stent+
atherectomy (1%). At 24-months post-procedure (N¼3,721), the atherectomy group
had the lowest mean healthcare costs ($49,588) while bypass had the highest
($62,340). After controlling for covariates, there were no statistically signiﬁcant dif-
ferences between atherectomy and any of the other treatments with respect to all-cause
health care costs over 24 months. Atherectomy patients were also not statistically
signiﬁcantly more likely than any of the other therapies to be hospitalized during
follow-up.
Conclusions: Diabetics tend to have a higher re-stenosis rate and are thought to have
more complex disease versus non-diabetic patients. Among PAD patients with dia-
betes in this large claims database, directional atherectomy was associated with similar
re-hospitalization rates and similar or lower costs compared to other PAD therapies
over 24 months.Thrombectomy
Washington Convention Center, Lower Level, Hall A
Saturday, September 13, 2014, 5:00 PM–7:00 PM
Abstract nos: 133-144
TCT-133
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Background: Patients with ST-elevation myocardial infarction (STEMI) treated
with primary angioplasty tend to have worse procedural results due to the presence of
larger amount of residual intrastent thrombus. However little is known about the
relationship between residual intrastent thrombus and clinical outcome. Aim of the
present study was to explore the correlation between the amount of residual intrastent
thrombus burden and the clinical outcome in patients enrolled in the randomized
COCTAIL II trial
Methods: The study population consisted of 128 STEMI patients who underwent
primary PCI within 6 h from onset of chest pain and randomized to one of the
following four treatments: local infusion of abciximab delivered by the ClearWay with
(group 1) or without thrombectomy (group 2), intracoronary abciximab with (group 3)
or without thrombectomy (group 4). Residual intrastent thrombus burden at OCT
assessment was deﬁned as: number of cross section with residual thrombus
area >10% and mean Thrombus area % (average of % thrombus area in all stented
cross sections). All patients had a clinical assessment at a mean follow-up of 12  4
months./Suppl B j September 13–17, 2014 j TCT Abstracts/Thrombectomy
www.jacctctabstracts2014.com SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PMResults: OCT assessment was available in 119 patients. Nine had a MACE (peri-
procedural myocardial infarction, myocardial infarction during follow-up or cardiac
death), while 110 had no complications (control group). The control group showed a
smaller number of cross section with residual thrombus area >10% respect to MACE
group (8.269.49 vs 16.0012.25; P¼ 0.02) and a smaller mean Thrombus area %
(4.712.64 vs 6.332.94, p¼ 0.08).
Conclusions: Residual intrastent thrombus is associated with higher incidence of
cardiac events during follow-up in STEMI patients treated with primary angioplasty
despite the adoption of aggressive strategy for thrombus removal.
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Background: Recent Frequency Domain Optical Coherence Tomography (FD-OCT)
studies showed that, even with the use of aggressive technical solutions, a
complete removal of thrombotic materials is rarely achieved after percutaneous
coronary interventions (PCI) for ST-segment elevation myocardial infarction
(STEMI). Residual intra-stent thrombus can result in distal embolization leading to
microcirculatory injury. The aim of this study was to ﬁnd a possible correlation be-
tween residual intrastent thrombus and angiographic indexes of myocardial
reperfusion.
Methods: COCTAIL II enrolled 128 STEMI patients which underwent primary PCI
within 6 h from onset of chest pain and randomized to one of the following four
treatments: local infusion of abciximab delivered by the ClearWay with (group 1) or
without thrombectomy (group 2), intracoronary abciximab with (group 3) or without
thrombectomy (group 4). Intrastent thrombus at OCT assessment was deﬁned as the
maximum % value of Thrombus area (thrombus area/stent area x 100 in the cross
section with largest thrombus). A value > 16% was considered indicative of high
residual intrastent thrombus. By study design the following angiographic indexes of
myocardial reperfusion were evalueted: TIMI value, corrected TIMI Frame Count
(cTFC) and Myocardial Blush Grade (MBG)
Results: Finally the OCT data were available in 119 patients: 64 had a maximum %
value of Thrombus area  16%, whilst the remaining 55 had a residual intrastent
thrombus >16%. No differences were found between the two groups regarding the
microcirculatory indexes at baseline angiogram. After intervention patients with
intrastent thrombus 16% showed a signiﬁcant improvement in the ﬁnal TIMI value
(2.870.33 vs 2.670.54; p¼0.014) and ﬁnal cTFC (11.714.58vs 17.4417.44; p¼
0.012). No statistically signiﬁcant differences were found for MBG (2.580.59 vs
2.430.76; p¼ 0.254.
Conclusions: Data obtained from the COCATIL II study suggest that the presence of
high residual intrastent thrombus in patients undergoing primary angioplasty is
associated with worsened ﬁnal microcirculatory indexes .
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Background: The utility of manual thrombectomy in patients with ST-elevation
myocardial infarction (STEMI) has been questioned after the recent publication of
the TASTE study (N¼7244). This study was larger than all combined previous
trials published to date and it found no beneﬁt with manual thrombectomy for the
primary outcome of all cause mortality. With these new ﬁndings, we sought to
perform an updated meta-analysis of randomized clinical trials with a focus on clinical
outcomes.
Methods: Medline, Embase and Cochrane detabase as well as conference proceeding
from major cardiology meetings were searched for randomized trials comparing
manual aspiration thrombectomy in addition to percutaneous coronary intervention
(PCI) versus PCI alone in patients presenting with STEMI.
Results: A total of 19 randomized controlled trials enrolled 11,197 patients
presenting with STEMI to either manual thrombectomy and PCI or conventional
PCI. There was a non signiﬁcant trend toward reduction in all cause death with
manual thrombectomy vs. PCI alone (2.9% vs. 3.5% with an odds ratio (OR) of 0.82
(95% CI: 0.66 to 1.01; p¼0.06)). Manual thrombectomy was associated with a
reduction in the incidence of re-infarction (OR: 0.61; 95% CI: 0.42 to 0.88; p¼0.008),
stent thrombosis (OR: 0.54; 95% CI: 0.32 to 0.93; p¼0.02), target lesion revascu-
larization (OR: 0.67; 95% CI: 0.5 to 0.91; p¼ 0.01) and rehospitalisation for
heart failure (OR: 0.25; 95% CI: 0.09 to 0.71; p¼ 0.009). Manual thrombectomy was
not associated with an increase in the risk of stroke (OR: 1.08; 95% CI: 0.62 to 1.87;
p¼ 0.8)).JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/ThConclusions: Manual thrombectomy reduced the incidence of myocardial re-infarc-
tion, stent thrombosis, target lesion revascularization and rehospitalisation for heart
failure. Further large scale trials are needed to determine the effect of thrombectomy
on mortality.
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Background: The purpose of this observational study was to evaluate the impact of
thrombectomy on in-stent restenosis and stent thrombosis in patients undergoing
primary PCI due to ST-elevation myocardial infarction (STEMI).
Methods: Data were obtained from the SCAAR registry (Swedish Coronary Angi-
ography and Angioplasty Registry) for PCI procedures performed in the county of
Västra Götaland in Sweden between January 2005 and May 2013. The primary
combined endpoint was in-stent restenosis and stent thrombosis. The study population
consisted of 9058 stents that were used in 6595 procedures on 5388 patients. The two
groups were compared using propensity score adjusted multilevel Cox proportional-
hazards regression to account for hierarchical database. Stents were the primary
observation unit, while patients and hospitals were two additional hierarchical clusters.
Adjustments for differences in baseline characteristics were made with propensity
score. The following variables were included in the calculation of the propensity
score: age, gender, indication for PCI, smoking habits, hypertension, diabetes,
hyperlipidaemia, severity of coronary artery disease, previous infarction, previous
PCI, previous coronary artery by-pass surgery (CABG), anticoagulation therapy with
glycoprotein IIb/IIIa receptor antagonists (GP IIb/IIIa), bivalirudin, clopidogrel,
ticagrelor, prasugrel, unfractionated heparin/low-molecular weight heparins (UH/
LMWH), year, hospital, completeness of revascularization, stent length, stent
diameter.
Results: The two groups were balanced regarding age, gender, diabetes, smoking
habits, hypertension, hyperlipidaemia, previous PCI, previous CABG. Patients who
were treated with thrombectomy were more likely to be completely revascularized,
pre-treated with aspirin and clopidogrel, and to receive bivalirudin and drug-eluting
stents during the procedure. Mean follow-up time was 3.3 years. After adjustment, the
use of thrombectomy was not associated with lower risk for stent thrombosis and
restenosis (HR 1.14; 95% CI 0.81–1.63; P ¼ 0.45).
Conclusions: In patients with STEMI, treatment with thrombectomy was not asso-
ciated with decreased risk for in-stent restenosis and stent thrombosis.
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Background: The clinical outcome of intracoronary thrombus aspiration before pri-
mary percutaneous coronary intervention (PCI) in patients with ST-segment elevation
myocardial infarction (STEMI) is controversial. Effective thrombectomy treatment on
myocardial damage has not been evaluated comprehensively. The main goal of this
study is to examine clinical impact of effective thrombectomy (ET) and non-effective
thrombectomy (non-ET)
Methods: We prospectively included 395 patients with TIMI 0 or I ﬂow anterior
STEMI, who underwent p-PCI with thrombus aspiration within 12 hours from
symptom onset. Manual thrombus aspiration devices (6f VMAX Asp. Catheter,
ASTRON, Germany,crossing proﬁle,0.068 in) were used for thrombectomy. Effective
thrombectomy (ET) was deﬁned as achieved visible aspiration material.Non-ET was
deﬁned as no visible aspiration material. No-reﬂow was deﬁned as TIMI grade 0, 1
and 2 ﬂows or TIMI grade 3 with myocardial blush grade 0 and 1. The primary end
points were the occurrence of no-reﬂow and the rate of 90-min ST-segment resolution
>70%. Patients were divided into two groups (ETandnonETgroups) according to their
aspiration materials
Results: Effective thrombectomy was observed 178 (60.3%) of patients. No-
reﬂow was lower in ET group compared with non-ET group 28 (15.7%) and
47 (40.2%), p< 0,001). Baseline clinical and demographic characteristics of the
study were similar. Ejection fraction (EF) and ST-segment resolution were higher,
and hospital mortality, Killip class II-IV and Post-pPCI TIMI frame count were
lower in ET group compared with non-ET group (p< 0.05 for all). Infarction
time, total stent length (mm), initial SYNTAX score, post-primary PCI SYNTAX
score and use of IIb/IIIa glycoprotein inhibitors were similar in two groups (p>0.05
for all).rombectomy B41
